Pre-emptive, early, and delayed alendronate treatment in a rat model of knee osteoarthritis: Effect on subchondral trabecular bone microarchitecture and cartilage degradation of the tibia, bone/cartilage turnover, and joint discomfort

Osteoarthritis and Cartilage

Volumn 21, Issue 10, 2013, Pages 1595-1604

  Mohan, G ^a,b   Perilli, E ^a,b   Parkinson, I H ^a,b   Humphries, J M ^a,b   Fazzalari, N L ^a,b   Kuliwaba, J S ^a,b  

^a HANSON INSTITUTE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Alendronate; Animal model; Invivo micro CT; Monosodium iodoacetate; Osteoarthritis; Subchondral trabecular bone

Indexed keywords

ALENDRONIC ACID; COLLAGEN TYPE 1; COLLAGEN TYPE 2; IODOACETIC ACID; PROTEOGLYCAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MASS; BONE TURNOVER; CARTILAGE; CARTILAGE DEGENERATION; CONTROLLED STUDY; DRUG EFFICACY; HISTOPATHOLOGY; IN VIVO STUDY; KNEE OSTEOARTHRITIS; MALE; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; PROTEIN URINE LEVEL; RAT; THERAPY DELAY; TIBIA; TRABECULAR BONE;

ALENDRONATE; ANIMAL MODEL; IN VIVO MICRO-CT; MONOSODIUM IODOACETATE; OSTEOARTHRITIS; SUBCHONDRAL TRABECULAR BONE;

ALENDRONATE; ANIMALS; ARTHRITIS, EXPERIMENTAL; BONE DENSITY CONSERVATION AGENTS; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CARTILAGE, ARTICULAR; COLLAGEN TYPE I; COLLAGEN TYPE II; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; MALE; OSTEOARTHRITIS, KNEE; PEPTIDE FRAGMENTS; PEPTIDES; RATS; RATS, WISTAR; TIBIA; X-RAY MICROTOMOGRAPHY;

EID: 84884165424     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2013.06.020     Document Type: Article

References (40)

1. Buckwalter J.A., Saltzman C., Brown T. The impact of osteoarthritis: implications for research. Clin Orthop Relat Res 2004, S6-S15.
2. Radin E.L., Rose R.M. Role of subchondral bone in the initiation and progression of cartilage damage. Clin Orthop Relat Res 1986, 34-40.
3. Bailey A.J., Mansell J.P., Sims T.J., Banse X. Biochemical and mechanical properties of subchondral bone in osteoarthritis. Biorheology 2004, 41:349-358.
4. Burr D.B. Anatomy and physiology of the mineralized tissues: role in the pathogenesis of osteoarthrosis. Osteoarthritis Cartilage 2004, 12(Suppl A):S20-S30.
5. Cohen S.B. An update on bisphosphonates. Curr Rheumatol Rep 2004, 6:59-65.
6. Buckland-Wright J.C., Messent E.A., Bingham C.O., Ward R.J., Tonkin C. A2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients. Rheumatology (Oxford) 2007, 46:257-264.
7. Spector T.D., Conaghan P.G., Buckland-Wright J.C., Garnero P., Cline G.A., Beary J.F., et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. Arthritis Res Ther 2005, 7:R625-R633.
8. Bingham C.O., Buckland-Wright J.C., Garnero P., Cohen S.B., Dougados M., Adami S., et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 2006, 54:3494-3507.
9. Carbone L.D., Nevitt M.C., Wildy K., Barrow K.D., Harris F., Felson D., et al. The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum 2004, 50:3516-3525.
10. Neogi T., Nevitt M.C., Ensrud K.E., Bauer D., Felson D.T. The effect of alendronate on progression of spinal osteophytes and disc-space narrowing. Ann Rheum Dis 2008, 67:1427-1430.
11. Hayami T., Pickarski M., Wesolowski G.A., McLane J., Bone A., Destefano J., et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum 2004, 50:1193-1206.
12. Shirai T., Kobayashi M., Nishitani K., Satake T., Kuroki H., Nakagawa Y., et al. Chondroprotective effect of alendronate in a rabbit model of osteoarthritis. JOrthop Res 2011, 29:1572-1577.
13. Zhang L., Hu H., Tian F., Song H., Zhang Y. Enhancement of subchondral bone quality by alendronate administration for the reduction of cartilage degeneration in the early phase of experimental osteoarthritis. Clin Exp Med 2011, 11:235-243.
14. Zhu S., Chen K., Lan Y., Zhang N., Jiang R., Hu J. Alendronate protects against articular cartilage erosion by inhibiting subchondral bone loss in ovariectomized rats. Bone 2013, 53:340-349.
15. Mohan G., Perilli E., Kuliwaba J.S., Humphries J.M., Parkinson I.H., Fazzalari N.L. Application of invivo micro-computed tomography in the temporal characterisation of subchondral bone architecture in a rat model of low-dose monosodium iodoacetate-induced osteoarthritis. Arthritis Res Ther 2011, 13:R210.
16. Strassle B.W., Mark L., Leventhal L., Piesla M.J., Jian Li X., Kennedy J.D., et al. Inhibition of osteoclasts prevents cartilage loss and pain in a rat model of degenerative joint disease. Osteoarthritis Cartilage 2010, 18:1319-1328.
17. Compston J. Bone quality: what is it and how is it measured?. Arq Bras Endocrinol Metabol 2006, 50:579-585.
18. Dempster D.W. The contribution of trabecular architecture to cancellous bone quality. JBone Miner Res 2000, 15:20-23.
19. Perilli E., Le V., Ma B., Salmon P., Reynolds K., Fazzalari N.L. Detecting early bone changes using invivo micro-CT in ovariectomized, zoledronic acid-treated, and sham-operated rats. Osteoporos Int 2010, 21:1371-1382.
20. Bove S.E., Calcaterra S.L., Brooker R.M., Huber C.M., Guzman R.E., Juneau P.L., et al. Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis. Osteoarthritis Cartilage 2003, 11:821-830.
21. Pomonis J.D., Boulet J.M., Gottshall S.L., Phillips S., Sellers R., Bunton T., et al. Development and pharmacological characterization of a rat model of osteoarthritis pain. Pain 2005, 114:339-346.
22. Hayami T., Pickarski M., Zhuo Y., Wesolowski G.A., Rodan G.A., Duong le T. Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis. Bone 2006, 38:234-243.
23. Pritzker K.P., Gay S., Jimenez S.A., Ostergaard K., Pelletier J.P., Revell P.A., et al. Osteoarthritis cartilage histopathology: grading and staging. Osteoarthritis Cartilage 2006, 14:13-29.
24. Frost H.M. Bone Histomorphometry: Analysis of Trabecular Bone Dynamics 1983, 109-131. CRC Press, Inc., Florida.
25. Holm S. Asimple sequentially rejective multiple test procedure. Scand J Stat 1979, 6:65-70.
26. Bobinac D., Spanjol J., Zoricic S., Maric I. Changes in articular cartilage and subchondral bone histomorphometry in osteoarthritic knee joints in humans. Bone 2003, 32:284-290.
27. Chappard C., Peyrin F., Bonnassie A., Lemineur G., Brunet-Imbault B., Lespessailles E., et al. Subchondral bone micro-architectural alterations in osteoarthritis: a synchrotron micro-computed tomography study. Osteoarthritis Cartilage 2006, 14:215-223.
28. Fazzalari N.L., Parkinson I.H. Femoral trabecular bone of osteoarthritic and normal subjects in an age and sex matched group. Osteoarthritis Cartilage 1998, 6:377-382.
29. Botter S.M., van Osch G.J., Waarsing J.H., Day J.S., Verhaar J.A., Pols H.A., et al. Quantification of subchondral bone changes in a murine osteoarthritis model using micro-CT. Biorheology 2006, 43:379-388.
30. Ding M., Danielsen C.C., Hvid I. Age-related three-dimensional microarchitectural adaptations of subchondral bone tissues in guinea pig primary osteoarthrosis. Calcif Tissue Int 2006, 78:113-122.
31. Lahm A., Kreuz P.C., Oberst M., Haberstroh J., Uhl M., Maier D. Subchondral and trabecular bone remodeling in canine experimental osteoarthritis. Arch Orthop Trauma Surg 2006, 126:582-587.
32. Brouwers J.E., Lambers F.M., Gasser J.A., van Rietbergen B., Huiskes R. Bone degeneration and recovery after early and late bisphosphonate treatment of ovariectomized Wistar rats assessed by invivo micro-computed tomography. Calcif Tissue Int 2008, 82:202-211.
33. Mashiba T., Turner C.H., Hirano T., Forwood M.R., Johnston C.C., Burr D.B. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001, 28:524-531.
34. Jones M.D., Tran C.W., Li G., Maksymowych W.P., Zernicke R.F., Doschak M.R. Invivo microfocal computed tomography and micro-magnetic resonance imaging evaluation of antiresorptive and antiinflammatory drugs as preventive treatments of osteoarthritis in the rat. Arthritis Rheum 2010, 62:2726-2735.
35. Panahifar A., Maksymowych W.P., Doschak M.R. Potential mechanism of alendronate inhibition of osteophyte formation in the rat model of post-traumatic osteoarthritis: evaluation of elemental strontium as a molecular tracer of bone formation. Osteoarthritis Cartilage 2012, 20:694-702.
36. Saag K.G. Bisphosphonates for osteoarthritis prevention: "Holy Grail" or not?. Ann Rheum Dis 2008, 67:1358-1359.
37. Ivanavicius S.P., Ball A.D., Heapy C.G., Westwood F.R., Murray F., Read S.J. Structural pathology in a rodent model of osteoarthritis is associated with neuropathic pain: increased expression of ATF-3 and pharmacological characterisation. Pain 2007, 128:272-282.
38. Felson D.T., Chaisson C.E., Hill C.L., Totterman S.M., Gale M.E., Skinner K.M., et al. The association of bone marrow lesions with pain in knee osteoarthritis. Ann Intern Med 2001, 134:541-549.
39. Abramson S., Krasnokutsky S. Biomarkers in osteoarthritis. Bull NYU Hosp Jt Dis 2006, 64:77-81.
40. Bettica P., Cline G., Hart D.J., Meyer J., Spector T.D. Evidence for increased bone resorption in patients with progressive knee osteoarthritis: longitudinal results from the Chingford study. Arthritis Rheum 2002, 46:3178-3184.